The exact incidence of pembrolizumab-induced type 1 diabetes mellitus varies; expert consensus estimates the overall incidence of immune checkpoint inhibitor–associated diabetes mellitus (CIADM) at approximately 0.4 to 1.0%. However, according to one small retrospective review, ICI-induced diabetes occurred more frequently with pembrolizumab (2.2%) when compared with nivolumab (1%) and ipilimumab (0%) Observational data often suggest an association with programmed death-1 (PD-1)/programmed de...
Guidelines published by the American Society of Clinical Oncology address management of immune-related adverse events in patients treated with immune checkpoint inhibitors, including autoimmune diabetes resulting from pembrolizumab toxicity. The guidelines emphasize early recognition of abrupt insulin deficiency and diabetic ketoacidosis (DKA), but do not specifically note any evidence of preventive medications. The discussed management recommendations largely reflect expert consensus. Patients developing new cases of polyuria, polydipsia, weight loss, or lethargy should undergo prompt assessment of glucose, electrolytes, anion gap, ketones, and acid-base status, with C-peptide, insulin, and pancreatic autoantibodies obtained to support diagnosis without delaying treatment. When autoimmune diabetes is suspected, insulin initiation and urgent endocrinology consultation are recommended, with hospitalization appropriate if timely outpatient management is unavailable, even without estab...
READ MORE→
A search of the published medical literature revealed
4 studies investigating the researchable question:
Please provide an overview of pembrolizumab-induced diabetes type 1.
Level of evidence
C - Multiple studies with limitations or conflicting results
READ MORE→
[1] Chitnis SD, Mortazavi A. Clinical guideline highlights for the hospitalist: Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy. J Hosp Med. 2023;18(11):1013-1016. doi:10.1002/jhm.13097
[2] Wu L, Tsang V, Clifton-Bligh R, et al. Hyperglycemia in patients treated with immune checkpoint inhibitors: key clinical challenges and multidisciplinary consensus recommendations. J Immunother Cancer. 2025;13(6):e011271. Published 2025 Jun 8. doi:10.1136/jitc-2024-011271
[3] Hu Q, Fan Y, He P. Islet function impairment outcomes of immune checkpoint inhibitors in cancer patients: a systematic review and meta-analysis. Front Immunol. 2026;17:1669492. Published 2026 Mar 19. doi:10.3389/fimmu.2026.1669492
[4] Chen B, Liu J, Gan K, et al. A network meta-analysis of endocrine adverse events induced by immune checkpoint inhibitors in colorectal cancer. Front Immunol. 2026;17:1798732. Published 2026 Jul 10. doi:10.3389/fimmu.2026.1798732
[5] de Filette J, Andreescu CE, Cools F, Bravenboer B, Velkeniers B. A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors. Horm Metab Res. 2019;51(3):145-156. doi:10.1055/a-0843-3366
[6] Cheng R, Boparai M, Zhu X, Wu S. Increased Risk of Hyperglycemia in Advanced Urothelial Cancer Patients Treated with Enfortumab Vedotin: A Systematic Review and Meta-Analysis. Cancer Invest. 2025;43(5):293-304. doi:10.1080/07357907.2025.2502992